1
|
Shahim B, Redfors B, Stuckey TD, Liu M, Zhou Z, Witzenbichler B, Weisz G, Rinaldi MJ, Neumann F, Metzger DC, Henry TD, Cox DA, Duffy PL, Brodie BR, Srdanovic I, Madhavan MV, Mazzaferri EL, Mehran R, Ben‐Yehuda O, Kirtane AJ, Stone GW. On-Treatment Platelet Reactivity and Ischemic Outcomes in Patients With Diabetes Mellitus: Two-Year Results From ADAPT-DES. J Am Heart Assoc 2022; 12:e026482. [PMID: 36565189 PMCID: PMC9973569 DOI: 10.1161/jaha.122.026482] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/25/2022]
Abstract
Background Diabetes mellitus and high platelet reactivity (HPR) on clopidogrel are both associated with increased risk of ischemic events after percutaneous coronary intervention, but whether the HPR-associated risk of adverse ischemic events differs by diabetes mellitus status is unknown. Methods and Results ADAPT-DES (Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents) was a prospective, multicenter registry of patients treated with coronary drug-eluting stents. HPR was defined as P2Y12 reaction units >208 by the VerifyNow point-of-care assay. Cox multivariable analysis was used to assess whether HPR-associated risk of major adverse cardiac events (MACE; cardiac death, myocardial infarction, or stent thrombosis) varied for patients with insulin-treated diabetes mellitus (ITDM), non-ITDM, and no diabetes mellitus. Diabetes mellitus and HPR were included in an interaction analysis. Of 8582 patients enrolled, 2429 (28.3%) had diabetes mellitus, of whom 998 (41.1%) had ITDM. Mean P2Y12 reaction units were higher in patients with diabetes mellitus versus without diabetes mellitus, and HPR was more frequent in patients with diabetes mellitus. HPR was associated with consistently increased 2-year rates of MACE in patients with and without diabetes mellitus (Pinteraction=0.36). A significant interaction was present between HPR and non-insulin-treated diabetes mellitus versus ITDM for 2-year MACE (adjusted hazard ratio [HR] for non-ITDM, 2.28 [95% CI, 1.39-3.73] versus adjusted HR for ITDM, 1.02 [95% CI, 0.70-1.50]; Pinteraction=0.01). Conclusions HPR was more common in patients with diabetes mellitus and was associated with an increased risk of MACE in both patients with and without diabetes mellitus. In patients with diabetes mellitus, a more pronounced effect of HPR on MACE was present in lower-risk non-ITDM patients than in higher-risk patients with ITDM. Registration URL: https://clinicaltrials.gov/ct2/show/NCT00638794; Unique identifier: NCT00638794. ADAPT-DES (Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents).
Collapse
Affiliation(s)
- Bahira Shahim
- Clinical Trials CenterCardiovascular Research FoundationNew YorkNY,Deparment of MedicineKarolinska InstitutetStockholmSweden,Cardiology Unit, Karolinska University HospitalKarolinska InstitutetStockholmSweden
| | - Björn Redfors
- Clinical Trials CenterCardiovascular Research FoundationNew YorkNY,NewYork‐Presbyterian Hospital/Columbia University Irving Medical CenterNew YorkNY,Department of CardiologySahlgrenska University HospitalGothenburgSweden
| | - Thomas D. Stuckey
- LeBauer‐Brodie Center for Cardiovascular Research and Education/Cone HealthGreensboroNC
| | - Mengdan Liu
- Clinical Trials CenterCardiovascular Research FoundationNew YorkNY
| | - Zhipeng Zhou
- Clinical Trials CenterCardiovascular Research FoundationNew YorkNY
| | | | - Giora Weisz
- Clinical Trials CenterCardiovascular Research FoundationNew YorkNY,Montefiore Medical CenterBronxNY
| | | | - Franz‐Josef Neumann
- Division of Cardiology and Angiology IIHeart Center University of FreiburgBad KrozingenGermany
| | | | - Timothy D. Henry
- Minneapolis Heart Institute Foundation at Abbott Northwestern HospitalMinneapolisMN,The Carl and Edyth Lindner Center for Research and Education at The Christ HospitalCincinnatiOH
| | | | - Peter L. Duffy
- Reid Heart CenterFirstHealth of the CarolinasPinehurstNC
| | - Bruce R. Brodie
- LeBauer‐Brodie Center for Cardiovascular Research and Education/Cone HealthGreensboroNC
| | - Iva Srdanovic
- Clinical Trials CenterCardiovascular Research FoundationNew YorkNY
| | - Mahesh V. Madhavan
- Clinical Trials CenterCardiovascular Research FoundationNew YorkNY,NewYork‐Presbyterian Hospital/Columbia University Irving Medical CenterNew YorkNY
| | | | - Roxana Mehran
- Clinical Trials CenterCardiovascular Research FoundationNew YorkNY,The Zena and Michael A. Wiener Cardiovascular InstituteIcahn School of Medicine at Mount SinaiNew YorkNY
| | - Ori Ben‐Yehuda
- Clinical Trials CenterCardiovascular Research FoundationNew YorkNY,Deparment of MedicineKarolinska InstitutetStockholmSweden
| | - Ajay J. Kirtane
- Clinical Trials CenterCardiovascular Research FoundationNew YorkNY,Deparment of MedicineKarolinska InstitutetStockholmSweden
| | - Gregg W. Stone
- The Zena and Michael A. Wiener Cardiovascular InstituteIcahn School of Medicine at Mount SinaiNew YorkNY
| |
Collapse
|
2
|
Lahu S, Scalamogna M, Ndrepepa G, Menichelli M, Valina C, Hemetsberger R, Witzenbichler B, Bernlochner I, Joner M, Xhepa E, Hapfelmeier A, Kufner S, Sager HB, Mayer K, Kessler T, Laugwitz K, Richardt G, Schunkert H, Neumann F, Kastrati A, Cassese S. Prior Myocardial Infarction and Treatment Effect of Ticagrelor Versus Prasugrel in Patients With Acute Coronary Syndromes - A Post-hoc Analysis of the ISAR-REACT 5 Trial. J Am Heart Assoc 2022; 11:e027257. [PMID: 36515247 PMCID: PMC9798807 DOI: 10.1161/jaha.122.027257] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Abstract
Background The efficacy and safety of ticagrelor versus prasugrel in patients with acute coronary syndrome and prior myocardial infarction (MI) remain unstudied. We aimed to assess the treatment effect of ticagrelor versus prasugrel according to prior MI status in patients with ACS. Methods and Results Patients with acute coronary syndrome planned for an invasive strategy and randomized to ticagrelor or prasugrel in the ISAR-REACT (Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment) 5 trial were included. The primary end point was the composite of 1-year all-cause death, MI, or stroke; the secondary safety end point was the composite of 1-year Bleeding Academic Research Consortium type 3 to 5 bleeding. The study included 4015 patients (prior MI=631 patients; no prior MI=3384 patients). As compared with patients without prior MI, the primary end point occurred more frequently in patients with prior MI (12.6% versus 7.2%; hazard ratio [HR], 1.78 [95% CI, 1.38-2.29]); the secondary safety end point appears to differ little between patients with and without prior MI (5.8% versus 5.7%, respectively; HR, 1.02 [95% CI, 0.71-1.45]). With regard to the primary end point, ticagrelor versus prasugrel was associated with an HR of 1.62 (95% CI, 1.03-2.55) in patients with prior MI and an HR of 1.28 (95% CI, 0.99-1.65) in patients without prior MI (Pint=0.37). With regard to the secondary safety end point, ticagrelor versus prasugrel was associated with an HR of 1.28 (95% CI, 0.56-2.91) in patients with prior MI and an HR of 1.13 (95% CI, 0.82-1.55) in patients without prior MI (Pint=0.79). Conclusions Patients with acute coronary syndrome and prior MI are at higher risk for recurrent ischemic but not bleeding events. Prasugrel is superior to ticagrelor in reducing the risk of ischemic events without a tradeoff in bleeding regardless of prior MI status. Registration URL: https://www.clinicaltrials.gov; Unique identifier: NCT01944800.
Collapse
Affiliation(s)
- Shqipdona Lahu
- Klinik für Herz‐ und Kreislauferkrankungen, Deutsches Herzzentrum MünchenTechnische Universität MünchenMunichGermany,German Center for Cardiovascular Research (DZHK), Partner Site Munich Heart AllianceMunichGermany
| | - Maria Scalamogna
- Klinik für Herz‐ und Kreislauferkrankungen, Deutsches Herzzentrum MünchenTechnische Universität MünchenMunichGermany,Department of Advanced Biomedical SciencesUniversity of Naples Federico IINaplesItaly
| | - Gjin Ndrepepa
- Klinik für Herz‐ und Kreislauferkrankungen, Deutsches Herzzentrum MünchenTechnische Universität MünchenMunichGermany
| | | | - Christian Valina
- Department of Cardiology and Angiology IIUniversity Heart Center Freiburg ‐ Bad Krozingen, Standort Bad KrozingenBad KrozingenGermany
| | - Rayyan Hemetsberger
- Heart Center Bad Segeberg, Segeberger Kliniken GmbH, Bad SegebergBad SegebergGermany
| | | | - Isabell Bernlochner
- German Center for Cardiovascular Research (DZHK), Partner Site Munich Heart AllianceMunichGermany,Medizinische Klinik und Poliklinik Innere Medizin I (Kardiologie, Angiologie, Pneumologie), Klinikum rechts der IsarMunichGermany
| | - Michael Joner
- Klinik für Herz‐ und Kreislauferkrankungen, Deutsches Herzzentrum MünchenTechnische Universität MünchenMunichGermany,German Center for Cardiovascular Research (DZHK), Partner Site Munich Heart AllianceMunichGermany
| | - Erion Xhepa
- Klinik für Herz‐ und Kreislauferkrankungen, Deutsches Herzzentrum MünchenTechnische Universität MünchenMunichGermany
| | - Alexander Hapfelmeier
- Technical University of Munich, School of MedicineInstitute of AI and Informatics in MedicineMunichGermany,Technical University of Munich, School of MedicineInstitute of General Practice and Health Services ResearchMunichGermany
| | - Sebastian Kufner
- Klinik für Herz‐ und Kreislauferkrankungen, Deutsches Herzzentrum MünchenTechnische Universität MünchenMunichGermany
| | - Hendrik B. Sager
- Klinik für Herz‐ und Kreislauferkrankungen, Deutsches Herzzentrum MünchenTechnische Universität MünchenMunichGermany,German Center for Cardiovascular Research (DZHK), Partner Site Munich Heart AllianceMunichGermany
| | - Katharina Mayer
- Klinik für Herz‐ und Kreislauferkrankungen, Deutsches Herzzentrum MünchenTechnische Universität MünchenMunichGermany
| | - Thorsten Kessler
- Klinik für Herz‐ und Kreislauferkrankungen, Deutsches Herzzentrum MünchenTechnische Universität MünchenMunichGermany,German Center for Cardiovascular Research (DZHK), Partner Site Munich Heart AllianceMunichGermany
| | - Karl‐Ludwig Laugwitz
- German Center for Cardiovascular Research (DZHK), Partner Site Munich Heart AllianceMunichGermany,Medizinische Klinik und Poliklinik Innere Medizin I (Kardiologie, Angiologie, Pneumologie), Klinikum rechts der IsarMunichGermany
| | - Gert Richardt
- Heart Center Bad Segeberg, Segeberger Kliniken GmbH, Bad SegebergBad SegebergGermany
| | - Heribert Schunkert
- Klinik für Herz‐ und Kreislauferkrankungen, Deutsches Herzzentrum MünchenTechnische Universität MünchenMunichGermany,German Center for Cardiovascular Research (DZHK), Partner Site Munich Heart AllianceMunichGermany
| | - Franz‐Josef Neumann
- Department of Cardiology and Angiology IIUniversity Heart Center Freiburg ‐ Bad Krozingen, Standort Bad KrozingenBad KrozingenGermany
| | - Adnan Kastrati
- Klinik für Herz‐ und Kreislauferkrankungen, Deutsches Herzzentrum MünchenTechnische Universität MünchenMunichGermany,German Center for Cardiovascular Research (DZHK), Partner Site Munich Heart AllianceMunichGermany
| | - Salvatore Cassese
- Klinik für Herz‐ und Kreislauferkrankungen, Deutsches Herzzentrum MünchenTechnische Universität MünchenMunichGermany
| |
Collapse
|
3
|
Neumann F, Möllring A, Holling T, Biermann D, Kubisch C, Muntau A, Kozlik-Feldmann R, Klingel K, Santer R, Gottschalk U. Homozygosity for a 3 bp-deletion in BOLA3 Causes a Severe Cardiac Phenotype in Early Childhood with Lethal Outcome. Thorac Cardiovasc Surg 2022. [DOI: 10.1055/s-0042-1742963] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Affiliation(s)
- F. Neumann
- Department of Pediatr Cardiology, Children's Heart Clinic, Univ Med Center Eppendorf, Hamburg, Deutschland
| | - A. Möllring
- Inst of Hum Genetics, Univ Med Center Eppendorf, Hamburg, Deutschland
| | - T. Holling
- Inst of Hum Genetics, Univ Med Center Eppendorf, Hamburg, Deutschland
| | - D. Biermann
- Department for Congen & Pediatr Heart Surgery, Children's Heart Clinic, Univ Med Center Eppendorf, Hamburg, Deutschland
| | - C. Kubisch
- Inst of Hum Genetics, Univ Med Center Eppendorf, Hamburg, Deutschland
| | - A. Muntau
- Department of Pediatr, Univ Med Center Eppendorf, Hamburg, Deutschland
| | - R. Kozlik-Feldmann
- Department of Pediatr Cardiology, Children's Heart Clinic, Univ Med Center Eppendorf, Hamburg, Deutschland
| | - K. Klingel
- Cardiopathology, Inst for Pathology and Neuropathology, Univ Hospital, Tübingen, Deutschland
| | - R. Santer
- Department of Pediatr, Univ Med Center Eppendorf, Hamburg, Deutschland
| | - U. Gottschalk
- Department of Pediatr Cardiology, Children's Heart Clinic, Univ Med Center Eppendorf, Hamburg, Deutschland
| |
Collapse
|
4
|
Neumann F, Kehl T, Plotnicki K, Neumann S, Müller G, Kozlik-Feldmann R, Lang N. Midterm Follow-up Using Lifetech Konar-MF Device for Perimembranous and Muscular Ventricular Septal Defects in Pediatric Patient's. Thorac Cardiovasc Surg 2022. [DOI: 10.1055/s-0042-1742977] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Affiliation(s)
- F. Neumann
- Department of Pediatr Cardiology, Children's Heart Clinic, University Med Center Eppendorf, Hamburg, Deutschland
| | - T. Kehl
- Department of Pediatr Cardiology, Children's Heart Clinic, University Med Center Eppendorf, Hamburg, Deutschland
| | - K. Plotnicki
- Department of Pediatr Cardiology, Children's Heart Clinic, University Med Center Eppendorf, Hamburg, Deutschland
| | - S. Neumann
- Department of Pediatr Cardiology, Children's Heart Clinic, University Med Center Eppendorf, Hamburg, Deutschland
| | - G. Müller
- Department of Pediatr Cardiology, Children's Heart Clinic, University Med Center Eppendorf, Hamburg, Deutschland
| | - R. Kozlik-Feldmann
- Department of Pediatr Cardiology, Children's Heart Clinic, University Med Center Eppendorf, Hamburg, Deutschland
| | - N. Lang
- Department of Pediatr Cardiology, Children's Heart Clinic, University Med Center Eppendorf, Hamburg, Deutschland
| |
Collapse
|
5
|
Schoechlin S, Hein M, Brennemann T, Eichenlaub M, Schulz U, Jander N, Neumann F. 5‐Year outcomes after transcatheter aortic valve implantation: Focus on paravalvular leakage assessed by echocardiography and hemodynamic parameters. Catheter Cardiovasc Interv 2022; 99:1582-1589. [DOI: 10.1002/ccd.30083] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/26/2021] [Accepted: 01/05/2022] [Indexed: 11/08/2022]
Affiliation(s)
- Simon Schoechlin
- Department of Cardiology and Angiology II University Heart Center Freiburg‐Bad Krozingen Bad Krozingen Germany
| | - Manuel Hein
- Department of Cardiology and Angiology II University Heart Center Freiburg‐Bad Krozingen Bad Krozingen Germany
| | - Tim Brennemann
- Department of Cardiology and Angiology II University Heart Center Freiburg‐Bad Krozingen Bad Krozingen Germany
| | - Martin Eichenlaub
- Department of Cardiology and Angiology II University Heart Center Freiburg‐Bad Krozingen Bad Krozingen Germany
| | - Undine Schulz
- Department of Cardiology and Angiology II University Heart Center Freiburg‐Bad Krozingen Bad Krozingen Germany
| | - Nikolaus Jander
- Department of Cardiology and Angiology II University Heart Center Freiburg‐Bad Krozingen Bad Krozingen Germany
| | - Franz‐Josef Neumann
- Department of Cardiology and Angiology II University Heart Center Freiburg‐Bad Krozingen Bad Krozingen Germany
| |
Collapse
|
6
|
Madduri D, Parekh S, Campbell T, Neumann F, Petrocca F, Jagannath S. Anti-BCMA-CAR-T-Zell-Therapie bei einem Patienten mit rezidiviertem und refraktärem Multiplen Myelom nach einer COVID-19-Infektion: ein Fallbericht. Kompass Onkol 2022. [PMCID: PMC9059054 DOI: 10.1159/000522435] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
Hintergrund: Über das Risiko einer Virusinfektion mit dem schweren akuten Atemwegssyndrom Coronavirus 2 (SARS-CoV-2) bei Krebspatienten, von denen viele immungeschwächt und damit anfälliger für eine Vielzahl von Infektionen sind, ist sehr wenig bekannt. Als Vorsichtsmaßnahme haben viele klinische Studien während der ersten Welle der weltweiten Pandemie des neuartigen Coronavirus (COVID-19) die Aufnahme von Patienten pausiert. In diesem Fallbericht beschreiben wir die erfolgreiche Behandlung eines Patienten mit rezidiviertem und refraktärem Multiplem Myelom (MM), der unmittelbar nach der klinischen Genesung von COVID-19 mit einer chimären Antigenrezeptor (CAR)-T-Zelltherapie mit Anti-B-Zellreifungsantigen (BCMA) behandelt wurde. Fallvorstellung: Der 57-jährige weiße männliche Patient war seit 4 Jahren an MM erkrankt und galt bei der Vorstellung zur CAR-T-Zelltherapie als pentarefraktär. Er hatte eine Immunsuppression in seiner medizinischen Vorgeschichte und er erhielt am Tag vor der COVID-19-Diagnose eine Dosis lymphdepletierender Chemotherapie (LDC). Dieser Patient konnte eine erhebliche Immunantwort gegen das SARS-CoV-2-Virus aufbauen, und antivirale Antikörper bleiben auch 2 Monate nach Erhalt einer Anti-BCMA-CAR-T-Zelltherapie noch nachweisbar. Die kürzliche SARS-CoV-2-Infektion bei diesem Patienten führte nicht zu einer Exazerbation des CAR-T-assoziierten Zytokin-Freisetzungssyndroms (CRS) und umgekehrt führte die CAR-T-Zelltherapie nicht zu Komplikationen im Zusammenhang mit COVID-19. Einen Monat nach der CAR-T-Zell-Infusion wurde bei dem Patienten ein unbestätigtes partielles Ansprechen nach den Kriterien der International Myeloma Working Group (IMWG) festgestellt. Schlussfolgerung: Unser Fall liefert einen wichtigen Kontext für die Wahl der Behandlung von MM-Patienten in Zeiten von COVID-19 sowie für die Frage, ob die CAR-T-Therapie auch bei Patienten verabreicht werden kann, die von COVID-19 genesen sind. Da die COVID-19-Pandemie weltweit anhält, ist eine umfangreiche Diskussion über die Entscheidung, ob mit der CAR-T-Zelltherapie fortgefahren werden soll, erforderlich, wobei die potenziellen Risiken und Vorteile der Therapie gegeneinander abgewogen werden müssen. Dieser Fall legt nahe, dass es möglich ist, die Anti-BCMA-CAR-T-Zelltherapie nach der Genesung von COVID-19 erfolgreich abzuschließen. Die Studie CRB-402 wurde am 6. September 2017 bei clinicaltrials.gov registriert (NCT03274219).
Collapse
Affiliation(s)
- D. Madduri
- Department of Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA
- *D. Madduri,
| | - S. Parekh
- Department of Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA
| | | | - F. Neumann
- bluebird bio, Cambridge, Massachusetts, USA
| | | | - S. Jagannath
- Department of Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA
| |
Collapse
|
7
|
Madduri D, Parekh S, Campbell TB, Neumann F, Petrocca F, Jagannath S. Anti-BCMA CAR T administration in a relapsed and refractory multiple myeloma patient after COVID-19 infection: a case report. J Med Case Rep 2021; 15:90. [PMID: 33608053 PMCID: PMC7894235 DOI: 10.1186/s13256-020-02598-0] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/26/2020] [Accepted: 11/23/2020] [Indexed: 11/30/2022] Open
Abstract
BACKGROUND Very little is known about the risk that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral infection poses to cancer patients, many of whom are immune compromised causing them to be more susceptible to a host of infections. As a precautionary measure, many clinical studies halted enrollment during the initial surge of the global Novel Coronavirus Disease (COVID-19) pandemic. In this case report, we detail the successful treatment of a relapsed and refractory multiple myeloma (MM) patient treated with an anti-B cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T cell therapy immediately following clinical recovery from COVID-19. CASE PRESENTATION The 57 year old Caucasian male patient had a 4-year history of MM and was considered penta-refractory upon presentation for CAR T cell therapy. He had a history of immunosuppression and received one dose of lymphodepleting chemotherapy (LDC) the day prior to COVID-19 diagnosis; this patient was able to mount a substantial immune response against the SARS-CoV-2 virus, and antiviral antibodies remain detectable 2 months after receiving anti-BCMA CAR T cell therapy. The recent SARS-CoV-2 infection in this patient did not exacerbate CAR T-associated cytokine release syndrome (CRS) and conversely the CAR T cell therapy did not result in COVID-19-related complications. One month after CAR T cell infusion, the patient was assessed to have an unconfirmed partial response per International Myeloma Working Group (IMWG) criteria. CONCLUSION Our case adds important context around treatment choice for MM patients in the era of COVID-19 and whether CAR T therapy can be administered to patients who have recovered from COVID-19. As the COVID-19 global pandemic continues, the decision of whether to proceed with CAR T cell therapy will require extensive discussion weighing the potential risks and benefits of therapy. This case suggests that it is possible to successfully complete anti-BCMA CAR T cell therapy after recovery from COVID-19. CRB-402 study registered 6 September 2017 at clinicaltrials.gov (NCT03274219).
Collapse
Affiliation(s)
- D. Madduri
- grid.59734.3c0000 0001 0670 2351Department of Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, 1 Gustave L Levy Pl, Box 1185, New York, NY 10029 USA
| | - S. Parekh
- grid.59734.3c0000 0001 0670 2351Department of Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, 1 Gustave L Levy Pl, Box 1185, New York, NY 10029 USA
| | | | - F. Neumann
- grid.434678.a0000 0004 0455 430Xbluebird bio, Cambridge, MA USA
| | - F. Petrocca
- grid.434678.a0000 0004 0455 430Xbluebird bio, Cambridge, MA USA
| | - S. Jagannath
- grid.59734.3c0000 0001 0670 2351Department of Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, 1 Gustave L Levy Pl, Box 1185, New York, NY 10029 USA
| |
Collapse
|
8
|
Schoechlin S, Minners J, Jadidi A, Abduljalil F, Ruile P, Neumann F, Arentz T. Effect of a restrictive pacemaker implantation strategy on mortality after transcatheter aortic valve implantation. Pacing Clin Electrophysiol 2021; 44:240-246. [DOI: 10.1111/pace.14156] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/22/2020] [Revised: 12/08/2020] [Accepted: 12/20/2020] [Indexed: 12/24/2022]
Affiliation(s)
- Simon Schoechlin
- Division of Cardiology and Angiology II University Heart Centre Freiburg Bad Krozingen Germany
| | - Jan Minners
- Division of Cardiology and Angiology II University Heart Centre Freiburg Bad Krozingen Germany
| | - Amir Jadidi
- Division of Cardiology and Angiology II University Heart Centre Freiburg Bad Krozingen Germany
| | - Fares Abduljalil
- Division of Cardiology and Angiology II University Heart Centre Freiburg Bad Krozingen Germany
| | - Philip Ruile
- Division of Cardiology and Angiology II University Heart Centre Freiburg Bad Krozingen Germany
| | - Franz‐Josef Neumann
- Division of Cardiology and Angiology II University Heart Centre Freiburg Bad Krozingen Germany
| | - Thomas Arentz
- Division of Cardiology and Angiology II University Heart Centre Freiburg Bad Krozingen Germany
| |
Collapse
|
9
|
Goel R, Cao D, Chandiramani R, Roumeliotis A, Blum M, Bhatt DL, Angiolillo DJ, Ge J, Seth A, Saito S, Krucoff M, Kozuma K, Makkar RM, Bangalore S, Wang L, Koo K, Neumann F, Hermiller J, Stefanini G, Valgimigli M, Mehran R. Comparative influence of bleeding and ischemic risk factors on diabetic patients undergoing percutaneous coronary intervention with everolimus‐eluting stents. Catheter Cardiovasc Interv 2020; 98:1111-1119. [DOI: 10.1002/ccd.29314] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/05/2020] [Revised: 08/18/2020] [Accepted: 09/21/2020] [Indexed: 11/10/2022]
Affiliation(s)
- Ridhima Goel
- The Zena and Michael A. Wiener Cardiovascular Institute Icahn School of Medicine at Mount Sinai New York City New York
| | - Davide Cao
- The Zena and Michael A. Wiener Cardiovascular Institute Icahn School of Medicine at Mount Sinai New York City New York
- Department of Biomedical Sciences Humanitas University Milan Italy
| | - Rishi Chandiramani
- The Zena and Michael A. Wiener Cardiovascular Institute Icahn School of Medicine at Mount Sinai New York City New York
| | - Anastasios Roumeliotis
- The Zena and Michael A. Wiener Cardiovascular Institute Icahn School of Medicine at Mount Sinai New York City New York
| | - Moritz Blum
- The Zena and Michael A. Wiener Cardiovascular Institute Icahn School of Medicine at Mount Sinai New York City New York
| | - Deepak L. Bhatt
- Brigham and Women's Hospital Heart & Vascular Center Harvard Medical School Boston Massachusetts
| | | | - Junbo Ge
- Zhongshan Hospital Fudan University Shanghai China
| | - Ashok Seth
- Fortis Escorts Heart Institute New Delhi India
| | | | | | - Ken Kozuma
- Division of Cardiology Teikyo University Tokyo Japan
| | | | - Sripal Bangalore
- Department of Cardiovascular Diseases New York University‐Langone Medical Center New York City New York
| | | | - Kai Koo
- Abbott Vascular Santa Clara California
| | - Franz‐Josef Neumann
- Department of Cardiology and Angiology II University Heart Center Freiburg Bad Krozingen Germany
| | - James Hermiller
- Division of Cardiovascular Medicine St Vincent Heart Center of Indiana Indianapolis Indiana
| | - Giulio Stefanini
- Department of Biomedical Sciences Humanitas University Milan Italy
| | - Marco Valgimigli
- Department of Cardiology Bern University Hospital Bern Switzerland
| | - Roxana Mehran
- The Zena and Michael A. Wiener Cardiovascular Institute Icahn School of Medicine at Mount Sinai New York City New York
| |
Collapse
|
10
|
Malejko K, Tumani V, Rau V, Neumann F, Plener PL, Fegert JM, Abler B, Straub J. Neural correlates of script-driven imagery in adolescents with interpersonal traumatic experiences: A pilot study. Psychiatry Res Neuroimaging 2020; 303:111131. [PMID: 32585577 DOI: 10.1016/j.pscychresns.2020.111131] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/06/2020] [Revised: 04/03/2020] [Accepted: 06/18/2020] [Indexed: 01/22/2023]
Abstract
In adults, trauma imagery has proven to be a useful tool to assess the neural mechanisms of psychological trauma processing. In adolescents, heterogeneous results could be found for other tasks, however, a trauma imagery paradigm has not been evaluated. For this purpose, we investigated a trauma imagery paradigm with control scripts to assess neural correlates of traumatic experiences in youth. 15 adolescents, who had experienced a traumatic interpersonal event in the past and have developed clinically relevant symptoms, underwent an fMRI scan while listening to their individual trauma- versus two control scripts (positive/negative). We analysed a parametric contrast of the imagery phases (trauma > negative > positive) which revealed activity in the thalamus, dorsal anterior cingulate cortex, cuneus, dorsomedial prefrontal cortex and amygdala. Additionally, amygdala-activity correlated positively with depression-symptom-severity. Our data provide evidence for the feasibility of fMRI during a trauma imagery task in adolescents to investigate networks previously related to hyperarousal in adults with PTSD. Further, we demonstrate the specificity of the activated networks for trauma imagery as compared to imagery of other emotional situations. The task might be particularly useful to evaluate neural correlates of treatment in adolescents when hyperarousal is a target symptom.
Collapse
Affiliation(s)
- K Malejko
- Ulm University, Department of Psychiatry and Psychotherapy III, Ulm, Germany.
| | - V Tumani
- Ulm University, Department of Psychiatry and Psychotherapy III, Ulm, Germany
| | - V Rau
- Ulm University, Department of Psychiatry and Psychotherapy III, Ulm, Germany
| | - F Neumann
- Ulm University, Department of Child and Adolescent Psychiatry and Psychotherapy, Ulm, Germany
| | - P L Plener
- Ulm University, Department of Child and Adolescent Psychiatry and Psychotherapy, Ulm, Germany; Medical University Vienna, Department of Child and Adolescent Psychiatry, Vienna, Austria
| | - J M Fegert
- Ulm University, Department of Child and Adolescent Psychiatry and Psychotherapy, Ulm, Germany
| | - B Abler
- Ulm University, Department of Psychiatry and Psychotherapy III, Ulm, Germany
| | - J Straub
- Ulm University, Department of Child and Adolescent Psychiatry and Psychotherapy, Ulm, Germany
| |
Collapse
|
11
|
Thurner L, Bewarder M, Fadle N, Regitz E, Poeschel V, Ziepert M, Schuck R, Altmeyer S, Kemele M, Bock T, Schormann C, Walter S, Szczepanowski M, Klapper W, Monoranu C, Rosenwald A, Moeller P, Kim Y, Buslei R, Kaddu-Mulindwa D, Neumann F, Roemer K, Bohle R, Illerhaus G, Schorb E, Schaefer H, Hansmann M, Hartmann S, Held G, Stilgenbauer S, Murawski N, Pfreundschuh M, Preuss K. SAMD14/NEURABIN-I AS BCR-ANTIGENS OF PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA. Hematol Oncol 2019. [DOI: 10.1002/hon.9_2630] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Affiliation(s)
- L. Thurner
- Saarland Medical School; Internal Medicine I, José Carreras Center; Homburg/Saar Germany
| | - M. Bewarder
- Saarland Medical School; Internal Medicine I, José Carreras Center; Homburg/Saar Germany
| | - N. Fadle
- Saarland Medical School; Internal Medicine I, José Carreras Center; Homburg/Saar Germany
| | - E. Regitz
- Saarland Medical School; Internal Medicine I, José Carreras Center; Homburg/Saar Germany
| | - V. Poeschel
- Saarland Medical School; Internal Medicine I, José Carreras Center; Homburg/Saar Germany
| | - M. Ziepert
- Universität Leipzig; Institute for Medical Informatics, Statistics, and Epidemiology; Leipzig Germany
| | - R. Schuck
- Saarland Medical School; Internal Medicine I, José Carreras Center; Homburg/Saar Germany
| | - S. Altmeyer
- Saarland Medical School; Internal Medicine I, José Carreras Center; Homburg/Saar Germany
| | - M. Kemele
- Saarland Medical School; Internal Medicine I, José Carreras Center; Homburg/Saar Germany
| | - T. Bock
- Saarland Medical School; Internal Medicine I, José Carreras Center; Homburg/Saar Germany
| | - C. Schormann
- Saarland Medical School; Internal Medicine I, José Carreras Center; Homburg/Saar Germany
| | - S. Walter
- Saarland Medical School; Department of Neurology; Homburg/Saar Germany
| | - M. Szczepanowski
- University of Kiel; Institute of Pathology, Hematopathology Section and Lymph Node Registry; Kiel Germany
| | - W. Klapper
- University of Kiel; Institute of Pathology, Hematopathology Section and Lymph Node Registry; Kiel Germany
| | - C. Monoranu
- University of Würzburg; Institute of Pathology and Neuropathology; Würzburg Germany
| | - A. Rosenwald
- University of Würzburg; Institute of Pathology and Neuropathology; Würzburg Germany
| | - P. Moeller
- University of Ulm; Department of Pathology; Ulm Germany
| | - Y. Kim
- Saarland Medical school; Department of pathology; Homburg/Saar Germany
| | - R. Buslei
- SozialStiftung Bamberg; Institute of Pathology; Bamberg Germany
| | - D. Kaddu-Mulindwa
- Saarland Medical School; Internal Medicine I, José Carreras Center; Homburg/Saar Germany
| | - F. Neumann
- Saarland Medical School; Internal Medicine I, José Carreras Center; Homburg/Saar Germany
| | - K. Roemer
- Saarland Medical School; Internal Medicine I, José Carreras Center; Homburg/Saar Germany
| | - R. Bohle
- Saarland Medical school; Department of pathology; Homburg/Saar Germany
| | - G. Illerhaus
- Klinikum Stuttgart; Department Hematology and Oncology; Stuttgart Germany
| | - E. Schorb
- University Medical Center Freiburg; Department of Hematology and Oncology; Freiburg Germany
| | - H. Schaefer
- University Medical Center Freiburg; Department of Hematology and Oncology; Freiburg Germany
| | - M.L. Hansmann
- Goethe University Frankfurt; Senckenberg Institute of Pathology; Frankfurt Germany
| | - S. Hartmann
- Goethe University Frankfurt; Senckenberg Institute of Pathology; Frankfurt Germany
| | - G. Held
- Saarland Medical School; Internal Medicine I, José Carreras Center; Homburg/Saar Germany
| | - S. Stilgenbauer
- Saarland Medical School; Internal Medicine I, José Carreras Center; Homburg/Saar Germany
| | - N. Murawski
- Saarland Medical School; Internal Medicine I, José Carreras Center; Homburg/Saar Germany
| | - M. Pfreundschuh
- Saarland Medical School; Internal Medicine I, José Carreras Center; Homburg/Saar Germany
| | - K.D. Preuss
- Saarland Medical School; Internal Medicine I, José Carreras Center; Homburg/Saar Germany
| |
Collapse
|
12
|
Hernández-Neuta I, Neumann F, Brightmeyer J, Ba Tis T, Madaboosi N, Wei Q, Ozcan A, Nilsson M. Smartphone-based clinical diagnostics: towards democratization of evidence-based health care. J Intern Med 2019; 285:19-39. [PMID: 30079527 PMCID: PMC6334517 DOI: 10.1111/joim.12820] [Citation(s) in RCA: 90] [Impact Index Per Article: 18.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
Abstract
Recent advancements in bioanalytical techniques have led to the development of novel and robust diagnostic approaches that hold promise for providing optimal patient treatment, guiding prevention programs and widening the scope of personalized medicine. However, these advanced diagnostic techniques are still complex, expensive and limited to centralized healthcare facilities or research laboratories. This significantly hinders the use of evidence-based diagnostics for resource-limited settings and the primary care, thus creating a gap between healthcare providers and patients, leaving these populations without access to precision and quality medicine. Smartphone-based imaging and sensing platforms are emerging as promising alternatives for bridging this gap and decentralizing diagnostic tests offering practical features such as portability, cost-effectiveness and connectivity. Moreover, towards simplifying and automating bioanalytical techniques, biosensors and lab-on-a-chip technologies have become essential to interface and integrate these assays, bringing together the high precision and sensitivity of diagnostic techniques with the connectivity and computational power of smartphones. Here, we provide an overview of the emerging field of clinical smartphone diagnostics and its contributing technologies, as well as their wide range of areas of application, which span from haematology to digital pathology and rapid infectious disease diagnostics.
Collapse
Affiliation(s)
- I Hernández-Neuta
- Department of Biochemistry and Biophysics, Science for Life Laboratory, Stockholm University, Solna, SE, Sweden
| | - F Neumann
- Department of Biochemistry and Biophysics, Science for Life Laboratory, Stockholm University, Solna, SE, Sweden
| | - J Brightmeyer
- Department of Chemical and Biomolecular Engineering, North Carolina State University, Raleigh, NC, USA
| | - T Ba Tis
- Department of Materials Science and Engineering, North Carolina State University, Raleigh, NC, USA
| | - N Madaboosi
- Department of Biochemistry and Biophysics, Science for Life Laboratory, Stockholm University, Solna, SE, Sweden
| | - Q Wei
- Department of Chemical and Biomolecular Engineering, North Carolina State University, Raleigh, NC, USA
| | - A Ozcan
- Electrical and Computer Engineering Department, University of California Los Angeles, Los Angeles, CA, USA
| | - M Nilsson
- Department of Biochemistry and Biophysics, Science for Life Laboratory, Stockholm University, Solna, SE, Sweden
| |
Collapse
|
13
|
Abdelghani M, Allali A, Kaur J, Hemetsberger R, Mehilli J, Neumann F, Frerker C, Kurz T, El‐Mawardy M, Richardt G, Abdel‐Wahab M. Impact of prosthesis‐iteration evolution and sizing practice on the incidence of prosthesis–patient mismatch after transcatheter aortic valve replacement. Catheter Cardiovasc Interv 2018; 93:971-979. [DOI: 10.1002/ccd.27977] [Citation(s) in RCA: 26] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/10/2018] [Revised: 10/15/2018] [Accepted: 10/23/2018] [Indexed: 11/10/2022]
Affiliation(s)
- Mohammad Abdelghani
- The Heart Center, Segeberger Kliniken Bad Segeberg Germany
- Cardiology Department, The Academic Medical CenterUniversity of Amsterdam Amsterdam The Netherlands
| | | | | | | | - Julinda Mehilli
- Munich University CenterLudwig‐Maximilians University Munich Germany
- German Centre for Cardiovascular Research (DZHK), Partner Site Munich Heart Alliance Munich Germany
| | | | | | - Thomas Kurz
- Cardiology DepartmentLübeck University Hospital Lübeck Germany
| | | | - Gert Richardt
- The Heart Center, Segeberger Kliniken Bad Segeberg Germany
| | - Mohamed Abdel‐Wahab
- The Heart Center, Segeberger Kliniken Bad Segeberg Germany
- Cardiology DepartmentHeart Center Leipzig, University Hospital Leipzig Germany
| |
Collapse
|
14
|
Heidrich J, Dengler D, Zyriax BC, Harth V, Schulz B, Westerhoff N, Langer-Böhmer S, Neumann F, Mache S, Okdenburg M. Concept of a multi-method study on health promotion and health care in commercial shipping. Eur J Public Health 2018. [DOI: 10.1093/eurpub/cky218.276] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Affiliation(s)
- J Heidrich
- Institute for Occupational and Maritime Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - D Dengler
- Institute for Occupational and Maritime Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - BC Zyriax
- Institute for Health Services Research in Dermatology and Nursing, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - V Harth
- Institute for Occupational and Maritime Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - B Schulz
- Institute for Occupational and Maritime Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - N Westerhoff
- Institute for Occupational and Maritime Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - S Langer-Böhmer
- Institute for Occupational and Maritime Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - F Neumann
- Institute for Health Services Research in Dermatology and Nursing, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - S Mache
- Institute for Occupational and Maritime Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - M Okdenburg
- Institute for Occupational and Maritime Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| |
Collapse
|
15
|
Brockmeier U, Kranz P, Ocklenburg T, Neumann F, Metzen E, Baumann M, Goepelt K, Hussmann M. PO-043 Targeting the thiol oxidoreductases ERp57 and PDI hits cancer cells on multiple fronts: proliferation, radioresistance and ER stress response (UPR). ESMO Open 2018. [DOI: 10.1136/esmoopen-2018-eacr25.87] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022] Open
|
16
|
Majidi F, Strapatsas J, Brille S, Fey I, Neumann F, Berger A, Germing U, Haas R, Gattermann N. Protein expression and clinical significance of the NEDDylation pathway in myelodysplastic syndrome. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy047.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
17
|
|
18
|
San Miguel J, Moreau P, Rajkumar V, Palumbo A, Facon T, Morgan G, Orlowski R, Cavo M, Einsele H, Neumann F, Labotka R, Lonial S, Richardson P. Four phase 3 studies of the oral proteasome inhibitor (PI) ixazomib for multiple myeloma in the newly-diagnosed, relapsed/refractory, and maintenance settings: TOURMALINE-MM1, -MM2, -MM3, and -MM4. Clinical Lymphoma Myeloma and Leukemia 2015. [DOI: 10.1016/j.clml.2015.07.397] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
19
|
Huggins C, Pierce S, Neumann F, Peri F, Cockerill G, Pirianov G. A novel small mimetic molecule TLR4 antagonist (IAXO-102) modulates TLR4 proinflammatory signalling and inhibits aortic aneurysms development. Atherosclerosis 2015. [DOI: 10.1016/j.atherosclerosis.2015.04.189] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
20
|
Kang Y, Ryoo B, Kim T, Lee K, Lim H, Lee S, Ikeda M, Okusaka T, Nadano S, Lin C, Poon T, Yen C, McCoon P, Neumann F, Vishwantahan K, DuPont R, Lyne P. 217 Results of a phase I, open-label, multicentre study to assess the safety, tolerability, pharmacokinetics and preliminary anti-tumour activity of AZD9150 in patients with advanced/metastatic hepatocellular carcinoma. Eur J Cancer 2014. [DOI: 10.1016/s0959-8049(14)70343-0] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
21
|
Stermann T, Neumann F, Osthold S, de Wendt C, Pujol A, Bosch F, Kragl M, Lammert E, Chadt A, Al-Hasani H. Funktionelle Analyse zur Rolle von Tbc1d1 in Langerhans'schen Inseln von Mäusen. DIABETOL STOFFWECHS 2014. [DOI: 10.1055/s-0034-1374875] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
22
|
Goffeney J, Dumont P, Neumann F, Chelabi R, Comte A, Amsallem D, Altuzarra C. SFP P-072 – Encéphalopathie épileptique précoce: à propos de 3 cas. Arch Pediatr 2014. [DOI: 10.1016/s0929-693x(14)72042-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
23
|
Caputo R, Leon M, Serruys P, Neumann F, Yeung A, Windecker S, Belardi JA, Silber S, Meredith I, Widimský P, Saito S, Mauri L. Performance of the resolute zotarolimus‐eluting stent in small vessels. Catheter Cardiovasc Interv 2014; 84:17-23. [DOI: 10.1002/ccd.25485] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/31/2013] [Revised: 03/02/2014] [Accepted: 03/10/2014] [Indexed: 11/10/2022]
Affiliation(s)
- Ronald Caputo
- St. Joseph's Hospital CardiologyLiverpool, New York New York
| | - Martin Leon
- Cardiovascular Research FoundationNew York New York
| | | | - Franz‐Josef Neumann
- HeartCenterUniversitäts‐Herzzentrum Freiburg‐Bad KrozingenBad Krozingen Germany
| | - Alan Yeung
- Stanford University School of MedicineStanford California
| | | | | | | | | | - Petr Widimský
- CardiocenterCharles, UniversityPrague Czech Republic
| | | | - Laura Mauri
- Brigham and Women's Hospital and Harvard Medical SchoolBoston Massachusetts
| |
Collapse
|
24
|
Doležalová L, Volšanský P, Neumann F, Denemark L. [Severe acute pancreatitis - managing complications using a combination of minimally invasive approaches]. Rozhl Chir 2014; 93:216-219. [PMID: 24881479] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/03/2023]
Abstract
In this case report, we describe the case of a 30-year-old obese patient with severe acute pancreatitis complicated during hospitalization by the development of infected necrosis, a pseudocyst and an abscess. We demonstrate a possible solution to these complications using a combination of minimally invasive approaches. The contribution of this case report resides in that it presents a combination of the percutaneous approach and the endosonographic approach in the treatment of pancreatic necrosis. We believe that in such an extensive necrosis of the pancreas as is described in our case, this combined approach is optimal. The condition for implementing such a procedure is a well-staffed and technically equipped workplace.
Collapse
|
25
|
Madej T, Szlapka M, Neumann F, Plötze K, Matschke K, Waldow T. Retrosternal gentamicin-collagen sponge does not reduce the incidence of mediastinitis in cardiac surgery. J Cardiothorac Surg 2013. [PMCID: PMC3844596 DOI: 10.1186/1749-8090-8-s1-o116] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022] Open
|
26
|
Assmann G, Zinke S, Ney JT, Ong MF, Neumann F, Nold S, Pfreundschuh M. SAT0286 Serum Immunoglobulin Free Light Chain Assessment in Psoriatic Arthritis. Ann Rheum Dis 2013. [DOI: 10.1136/annrheumdis-2013-eular.2011] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
27
|
Waldow T, Madej T, Neumann F, Plötze K, Matschke K. Retrosternal gentamicin-collagen sponge does not reduce the incidence of mediastinitis in cardiac surgery. Thorac Cardiovasc Surg 2013. [DOI: 10.1055/s-0032-1332486] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
28
|
van Diepen S, Newby L, Lopes R, Stebbins A, Hasselblad V, James S, Roe M, Ezekowitz J, Moliterno D, Neumann F, Reist C, Hochman J, Mahaffey K, Hamm C, Armstrong P, Granger C, Theroux P. 726 Acute Phase Inflammatory Biomarkers Add Little Predictive Value to Clinical Factors Plus NT-proBNP Among Patients With ST-Segment Elevation Myocardial Infarction: An Apex AMI Trial Substudy. Can J Cardiol 2012. [DOI: 10.1016/j.cjca.2012.07.657] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
|
29
|
Dokas J, Chadt A, Neumann F, Joost HG, Al-Hasani H. Analyse von TBC1D1 im Substrat- und Energiestoffwechsel anhand eines adipösen Mausmodells. DIABETOL STOFFWECHS 2011. [DOI: 10.1055/s-0031-1277347] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
30
|
Neumann F, Gompert M, Klein HW, Dokas J, Chadt A, Joost HG, Al-Hasani H. In vitro Charakterisierung des Rab-GTPase-aktivierenden Proteins TBC1D1. DIABETOL STOFFWECHS 2011. [DOI: 10.1055/s-0031-1277346] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
31
|
|
32
|
|
33
|
|
34
|
Michael M, Bruns I, Bölke E, Zohren F, Czibere A, Safaian NN, Neumann F, Haas R, Kobbe G, Fenk R. Bendamustine in patients with relapsed or refractory multiple myeloma. Eur J Med Res 2010; 15:13-9. [PMID: 20159666 PMCID: PMC3351842 DOI: 10.1186/2047-783x-15-1-13] [Citation(s) in RCA: 30] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/02/2022] Open
Abstract
Objective In patients with multiple myeloma, bendamustine monotherapy is effective as 1st and 2nd line therapy. However, data for patients with advanced multiple myeloma is rare. Methods In this retrospective analysis we have identified 39 patients with relapsed or refractory multiple myeloma by means of case research, who have been treated at our institution with bendamustine as salvage therapy. After in median 2 lines of prior therapy (range:1-5) patients received in median 3 (range: 1-10) cycles of bendamustine. Bendamustine dosage was 80-150 mg on day 1+2 of a monthly cycle. Bendamustine was administered as monotherapy in 39% of patients, whereas 61% received concomitant steroids. Results Toxicity was mild to moderate. Response rates were as follows: 3% vgPR, 33% PR, 18% MR, 26% SD and 20% PD. The median event-free and overall survival were 7 and 17 months, respectively. Conclusions In conclusion, in patients with advanced multiple myeloma bendamustine is effective and associated with mild toxicity. Therefore, the role of bendamustine in patients with multiple myeloma should be investigated in further clinical trials.
Collapse
Affiliation(s)
- M Michael
- Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine-University, Duesseldorf, Germany
| | | | | | | | | | | | | | | | | | | |
Collapse
|
35
|
Dokas J, Chadt A, Neumann F, Joost HG, Al-Hasani H. Funktion von TBC1D1 im Substrat- und Energiestoffwechsel. DIABETOL STOFFWECHS 2010. [DOI: 10.1055/s-0030-1253733] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
36
|
Neumann F, Kern J, Gompert M, Klein HW, Leicht K, De Simone A, Dokas J, Chadt A, Al-Hasani H. Ein in vitro Testverfahren zur Charakterisierung von TBC1D1. DIABETOL STOFFWECHS 2010. [DOI: 10.1055/s-0030-1253732] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
37
|
Mayinger B, Neumann F, Kastner C, Haider T, Schwab D. Hexaminolevulinate-induced fluorescence colonoscopy versus white light endoscopy for diagnosis of neoplastic lesions in the colon. Endoscopy 2010; 42:28-33. [PMID: 20066590 DOI: 10.1055/s-0029-1243804] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
BACKGROUND AND STUDY AIMS To compare the rate of detection of colorectal neoplastic lesions using the selective photosensitizer precursor hexaminolevulinate (HAL) combined with a new fluorescence video endoscope system against that of standard white light endoscopy, and secondarily, to evaluate the safety profile of HAL-induced fluorescence colonoscopy. PATIENTS AND METHODS This prospective phase II clinical pilot study from two hospital study centers included 25 patients with known or highly suspected colorectal neoplasia. They underwent sensitization with locally applied 500 ml HAL enemas at a concentration of 1.6 mmol/L. At 60 minutes after enteral HAL administration, fluorescence imaging was done using a special light source capable of delivering either white light or blue excitation light. Red fluorescence induced by illumination with blue light was detected via a prototype fluorescence video colonoscope. Biopsies were taken from suspicious areas found with white or blue light. RESULTS Using histology as the gold standard, 55 / 93 of neoplastic lesions were detected with white light endoscopy, 53 / 93 with both white and blue light, 38 / 93 with blue light and second-pass white light, and 27/93 with blue light only. Of all neoplastic lesions, 91 / 93 revealed red fluorescence under fluorescence imaging ( P < 0.0001). Fluorescence mode showed 38.7 % (36 / 93) more neoplasms than did white light endoscopy. An isolated slight elevation of bilirubin, by a factor of 1.5, was noted after the administration of HAL. CONCLUSIONS Administration of HAL as enema induces selective lesion fluorescence and increases lesion detection rate in patients with colorectal neoplasia, especially of flat, nonvisible adenomas.
Collapse
Affiliation(s)
- B Mayinger
- Department of Medicine II, Hospital Munich-Pasing, Teaching Hospital of the University of Munich (LMU), D-81241 Munich, Germany.
| | | | | | | | | |
Collapse
|
38
|
Latzke D, Marhofer P, Zeitlinger M, Machata A, Neumann F, Lackner E, Kettner SC. Minimal local anaesthetic volumes for sciatic nerve block: evaluation of ED 99 in volunteers. Br J Anaesth 2009; 104:239-44. [PMID: 20034967 DOI: 10.1093/bja/aep368] [Citation(s) in RCA: 77] [Impact Index Per Article: 5.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
BACKGROUND This randomized, double-blinded volunteer study was designed to evaluate the ED(99) volume of local anaesthetic for sciatic nerve blocks using a step-up/step-down methodology. METHODS A maximum of 20 volunteers were included to receive an ultrasound-guided sciatic nerve block with mepivacaine 1.5% and a starting volume of 0.2 ml mm(-2) cross-sectional nerve area. In cases of a complete sensory block, the volume was reduced by 0.02 ml mm(-2) cross-sectional nerve area until the first block failed. Thereafter, the volume of local anaesthetic was increased by 0.02 ml mm(-2) cross-sectional nerve area. After three cycles of successful/failed blocks, the ED(99) volume of local anaesthetic could be calculated by a probability function. The influence of the volumes of local anaesthetics on sensory onset times and duration of sensory block was evaluated by linear regression. RESULTS The ED(99) volume of local anaesthetic for sciatic nerve block was calculated with 0.10 ml mm(-2) cross-sectional nerve area. The correlation between the volume of local anaesthetic and the sensory onset time was weak (r=0.14), whereas the correlation between the volume of local anaesthetic and the duration of sensory block was moderate (r=0.65). CONCLUSIONS This is the first study where an ED(99) volume of local anaesthetic for sciatic nerve block has been evaluated. The resulting local anaesthetic volume of 0.10 ml mm(-2) cross-sectional nerve area seems to have no impact on sensory onset time, whereas the duration of sensory block is shorter.
Collapse
Affiliation(s)
- D Latzke
- Department of Anaesthesia, Intensive Care Medicine and Pain Therapy, Medical University of Vienna, Waehringer Guertel 18-20, A-1090 Vienna, Austria
| | | | | | | | | | | | | |
Collapse
|
39
|
Neumann F, Kalmus J. Cyproterone acetate in the treatment of sexual disorders: pharmacological base and clinical experience. Exp Clin Endocrinol 2009; 98:71-80. [PMID: 1838080 DOI: 10.1055/s-0029-1211103] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Abstract
Cyproterone acetate (CPA) has been discovered more than 25 years ago and it was the first antiandrogen suitable for clinical use. CPA inhibits the action of endogenous and exogenous androgens at all androgen target organs; these include the prostate, seminal vesicles, testes, and the vas deferens. However, this antiandrogen also antagonizes less sex-specific effects of androgens, for example ossification of the epiphyseal cartilage, sebaceous gland function and skin thickness. Indications for CPA: Prostate cancer, androgen induced disorders of the skin (acne, seborrhoea, hirsutism, alopecia), precocious puberty and sexual disorders in men. Concerning sexual deviations clinical trials started in 1966. CPA leads to loss of libido and the ability to achieve erection, followed by the inability to achieve orgasm, after about 14 days of treatment (100-200 mg daily orally or 300 mg weekly i.m.). These effects are reversed in the same order as the onset. About 75 to 80% of patients respond to this therapy. CPA is generally well tolerated. Tiredness, lack of drive, listlessness and depressive moods have been reported as non-specific side-effects. Slight gynecomastia occurs in about 20% of patients. There are no good alternatives in this indication. Pure antiandrogens are unsuitable, because these are unable to inhibit libido sufficiently. Tranquilizers are not very effective, high doses of estrogens are associated with severe (cardiovascular) side effects. Orchidectomy is an irreversible intervention, LHRH analogues are associated with hot flushes and the initial increase in testosterone (flare phenomenon).
Collapse
Affiliation(s)
- F Neumann
- Department of Clinical Research, Schering AG Berlin/Germany
| | | |
Collapse
|
40
|
Neumann F. The antiandrogen cyproterone acetate: discovery, chemistry, basic pharmacology, clinical use and tool in basic research. Exp Clin Endocrinol 2009; 102:1-32. [PMID: 8005205 DOI: 10.1055/s-0029-1211261] [Citation(s) in RCA: 63] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Affiliation(s)
- F Neumann
- Schering Research Foundation Ltd., Berlin/Bergkamen, Germany
| |
Collapse
|
41
|
Leschber G, Nishino Y, Neumann F. Influence of an Aromatase Inhibitor (4-Acetoxy-4-Androstene-3,17-Dione) on Experimentally Induced Impairment of Spermatogenesis in Immature Rats/Einfluß eines Aromatasehemmers (4-Acetoxy-4-Androsten-3,17-dion) auf die experimentell induzierte Hemmung der. Andrologia 2009. [DOI: 10.1111/j.1439-0272.1989.tb02465.x] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
|
42
|
Abstract
1. Steroid hormones can affect spermatogenesis and thereby fertility directly and/or indirectly. All antigonadotropically active steroids inhibit spermatogenesis via inhibition of gonadotropin secretion, mainly that of H. Androgens and steroids occurring in the biosynthetic chain of testosterone synthesis have a direct promoting effect on spermatogenesis if applied in high doses. It has not been possible as yet to make clinical use of this positive effect since it is obviously not possible to achieve the necessary intratesticular androgen concentrations. 2. As concerns the different androgens and the steroids in the androgen biosynthetic chain, and also all synthetic anabolics, there is no parallelism between the direct spermatogenic activity, the androgenic activity and the antigonadotropic activity. 3. Estrogens and synthetic gestagens do not inhibit spermatogenesis directly at the testicular level. All effects of estrogens can be abolished experimentally by adequate substitution with gonadotropins or androgens, or a combination of androgens and gonadotropins. 4. Only those antiandrogens inhibit spermatogenesis with additional antigonadotropic properties (e.g. cyproterone acetate). Pure antiandrogens, like flutamide or cyproterone, have a slight and transient influence on spermatogenesis at the most. If at all, they merely cause transient subfertility. 5. Beside steroids and several centrally active pharmaceutics (e.g. psychotropic drugs and several antihypertensive compounds), only siloxanes and methallibur seem to affect spermatogenesis via inhibition of gonadotropin secretion. Other antispermatogenic agents act by inhibition of mitosis (Colchicine, alkylating agents) or presumably via damage of the Sertoli cells. 6. Based on present knowledge, contraception in men could be principally managed by administration of a) androgens alone, b) gestagen/androgen combinations, c) estrogen/androgen combinations, d) certain antiandrogens. 7. The difficulties of contraception in men by steroid hormones or steroid hormone combinations have been pointed out. As regards the usefulness of antiandrogens for contraception, no definite conclusions can be drawn at the moment. All non-steroidal inhibitors of spermatogenesis which have been found up to the present are not suitable because of toxic effects.
Collapse
|
43
|
Bruennert D, Czibere A, Bruns I, Kronenwett R, Gattermann N, Haas R, Neumann F. Early in vivo changes of the transcriptome in Philadelphia chromosome-positive CD34+ cells from patients with chronic myelogenous leukaemia following imatinib therapy. Leukemia 2008; 23:983-5. [DOI: 10.1038/leu.2008.337] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
44
|
Rosskopf D, Schwahn C, Neumann F, Bornhorst A, Mischke M, Wolf S, Geissler I, Kocher T, Grabe HJ, Nauck M, Hebebrand J, Kroemer HK, Friedrich N, Völzke H, Wallaschofski H. The growth hormone – IGF1 axis as a mediator for association between FTO variants and obesity. Exp Clin Endocrinol Diabetes 2008. [DOI: 10.1055/s-0028-1096330] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
45
|
Pavel ME, Bartel C, Heuck F, Neumann F, Tiling N, Pape UF, Plöckinger U, Wiedenmann B. Open-label, non-randomized, multicenter phase II study evaluating the angiogenesis inhibitor PTK787/ ZK222584 (PTK/ZK) in patients with advanced neuroendocrine carcinomas (NEC). J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.14684] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
46
|
Radlmaier A, Bormacher K, Neumann F. Hitzewallungen bei Endokrintherapie des Prostatakarzinoms: Modellvorstellung zu ihrer Genese. Aktuelle Urol 2008. [DOI: 10.1055/s-2008-1061203] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
47
|
|
48
|
Tunn U, Weiβbach L, Neumann F, Schweikert H. Hypospadie als Folge eines gestörten Androgenstoffwechsels und als Symptom der Intersexualität. Aktuelle Urol 2008. [DOI: 10.1055/s-2008-1062951] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
49
|
Schacher A, El Etreby M, Neumann F. Einfluß von Cyproteronacetat, Flutamid und Spironolacton auf die Achse Hypothalamus- Hypophyse-Hoden bei Ratten. Aktuelle Urol 2008. [DOI: 10.1055/s-2008-1062645] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
50
|
Mayinger B, Neumann F, Kastner C, Degitz K, Hahn EG, Schwab D. Early detection of premalignant conditions in the colon by fluorescence endoscopy using local sensitization with hexaminolevulinate. Endoscopy 2008; 40:106-9. [PMID: 18197583 DOI: 10.1055/s-2007-967019] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
Abstract
BACKGROUND AND STUDY AIMS We aimed to determine the feasibility of obtaining selective fluorescence of precancerous/cancerous lesions in the colon with a new fluorescence video endoscope system in combination with the selective photosensitizer precursor hexaminolevulinate (HAL), and to carry out a dose-finding study with evaluation of the optimal dose and application time. PATIENTS AND METHODS 12 patients with colorectal lesions underwent sensitization with locally applied HAL enemas in two concentrations (0.8 mmol and 1.6 mmol). The examination was conducted either 30 or 60 minutes after rectal administration of the sensitizer, using a special light source capable of delivering either white or blue excitation light. Red fluorescence induced by illumination with blue light was detected via a prototype fluorescence video colonoscope. Biopsies were taken from suspicious areas found with white or blue light. Corresponding endoscopic, fluorescence, and microscopic findings were compared. RESULTS Using histological findings as the gold standard, 52/53 of the premalignant/malignant lesions showed red fluorescence under the photodynamic diagnosis (PDD) examination; 38/53 were detected with white-light endoscopy. The PDD mode showed 28 % more polyps than did white-light endoscopic imaging. The greatest fluorescence intensity in precancerous lesions was found with retention for 60 minutes of 500 ml of 1.6 mmol HAL. CONCLUSIONS Administration of HAL enema induces selective lesion fluorescence and increases the lesion detection rate in patients with colorectal adenoma and early carcinoma.
Collapse
Affiliation(s)
- B Mayinger
- Department of Medicine II, Hospital Munich-Pasing, Teaching Hospital of University of Munich (LMU), Munich, Germany.
| | | | | | | | | | | |
Collapse
|